Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENvue Medical (FEED) Finished Goods (2017 - 2025)

Historic Finished Goods for ENvue Medical (FEED) over the last 9 years, with Q3 2025 value amounting to $541000.0.

  • ENvue Medical's Finished Goods fell 7209.9% to $541000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $541000.0, marking a year-over-year decrease of 7209.9%. This contributed to the annual value of $1.8 million for FY2024, which is 2862.81% down from last year.
  • Latest data reveals that ENvue Medical reported Finished Goods of $541000.0 as of Q3 2025, which was down 7209.9% from $434000.0 recorded in Q2 2025.
  • Over the past 5 years, ENvue Medical's Finished Goods peaked at $2.1 billion during Q4 2022, and registered a low of $175000.0 during Q4 2021.
  • Its 5-year average for Finished Goods is $215.8 million, with a median of $1.9 million in 2024.
  • Per our database at Business Quant, ENvue Medical's Finished Goods skyrocketed by 122561428.57% in 2022 and then plummeted by 9988.24% in 2023.
  • Quarter analysis of 5 years shows ENvue Medical's Finished Goods stood at $175000.0 in 2021, then skyrocketed by 1225614.29% to $2.1 billion in 2022, then tumbled by 99.88% to $2.5 million in 2023, then dropped by 28.63% to $1.8 million in 2024, then plummeted by 69.94% to $541000.0 in 2025.
  • Its last three reported values are $541000.0 in Q3 2025, $434000.0 for Q2 2025, and $1.5 million during Q1 2025.